7.3 Breast Density Reporting Requirements

7.3 Breast Density Reporting Requirements

Quick Answer: As of September 10, 2024, every mammogram performed under an MQSA certificate — screening and diagnostic — must carry an interpreting-physician density assessment on the medical report and FDA's required density sentences on the patient lay summary. The mammographer explains that density will appear in the letter. The mammographer does not assign density. Quote FDA's statements; do not paraphrase them into a friendlier slogan.

ARRT added breast density reporting requirements under MQSA regulations in Image Production for the specifications implemented September 1, 2025. The exam addition tracks a real regulatory change, not a textbook trend. FDA issued the 2023 MQSA Final Rule on March 10, 2023. Enforcement of the amended regulations, including density notification, began September 10, 2024. FDA's own pages treat that September date as the day facilities must comply.

Why a federal sentence exists

Breast density is the amount of fibroglandular tissue as it appears on the mammogram. Dense tissue is white, and many cancers are white, so density can mask findings. Dense tissue is also an independent risk factor for developing breast cancer. FDA's patient-facing sentence puts both facts in one place: dense tissue "makes it harder to find breast cancer on a mammogram and also raises the risk of developing breast cancer." FDA has stated that approximately half of women over age 40 in the United States have dense breast tissue. Before the federal rule, some States required density notices and some did not, so two patients with the same mammogram could leave with different information depending on the ZIP code. The federal requirement is independent of State or local density laws. Facilities still must use the FDA report categories and the FDA lay-summary statements even if a State statute uses different wording.

Who assigns density — and who does not

The interpreting physician assigns overall breast density on the mammography report (21 CFR 900.12(c)(1)(vi)). The four FDA assessments, quoted as they appear in the regulation, are:

BI-RADS density letters (a through d) are an ACR reporting convention that maps onto the same four-point idea. MQSA inspectors look for FDA assessment language, not a BI-RADS number. A mammographer who says "you're a C" in the hallway has stepped out of the MQSA role. Compression difficulty, cup size, and how "firm" the breast felt are not density assignments. Density is a mammographic assessment made after the images are interpreted.

When a patient asks during positioning, "Do I have dense breasts?" the accurate technologist answer is: density is assigned by the interpreting physician on the report, and the lay letter the facility sends will include required FDA language about whether tissue was dense or not dense. Offer to make sure the patient knows how the facility delivers that letter (print at departure, portal, or mail). Do not preview a density category from the acquisition workstation. Do not tell the patient she needs ultrasound because her tissue "looked dense on the scout." Additional imaging, if any, is a conversation with her healthcare provider after the IP has reported.

Exact FDA lay-summary statements — do not rewrite them

21 CFR 900.12(c)(2)(iii) and (iv) specify the sentences. Facilities must include them. They are not optional talking points.

Not-dense statement (used when the report assessment is almost entirely fatty or scattered areas of fibroglandular density):

Breast tissue can be either dense or not dense. Dense tissue makes it harder to find breast cancer on a mammogram and also raises the risk of developing breast cancer. Your breast tissue is not dense. Talk to your healthcare provider about breast density, risks for breast cancer, and your individual situation.

Dense statement (used when the report assessment is heterogeneously dense or extremely dense):

Breast tissue can be either dense or not dense. Dense tissue makes it harder to find breast cancer on a mammogram and also raises the risk of developing breast cancer. Your breast tissue is dense. In some people with dense tissue, other imaging tests in addition to a mammogram may help find cancers. Talk to your healthcare provider about breast density, risks for breast cancer, and your individual situation.

Read the two blocks against each other. Both open with the same two sentences, so every patient hears that density can hide cancer and that density raises risk — even patients whose own tissue is not dense. The fork is "Your breast tissue is not dense" versus "Your breast tissue is dense," plus one extra sentence in the dense version about other imaging tests in some people. FDA did not write "you must have ultrasound," "your mammogram is useless," or "you have a 50 percent chance of cancer." Do not volunteer those paraphrases. The dense statement says other imaging tests may help in some people and tells the patient to talk with her healthcare provider about her individual situation.

Inspectors review sample lay letters for patient name; facility name, full address, and telephone number; and the federal breast density notification statement. A beautifully written custom paragraph that omits FDA's sentences fails. A letter that uses FDA's sentences and then adds facility-specific logistics (how to obtain images, when to expect a portal message) can still pass if the required statement is intact.

Screening and diagnostic — no MQSA carve-out

FDA's Small Entity Compliance Guide answers this directly: as of September 10, 2024, the density assessment belongs on the mammography report and the notification statement belongs on the lay summary for each mammographic examination performed under the certificate. There is no differentiation between screening and diagnostic mammograms, and no differentiation between unilateral and bilateral mammograms in the base rule (21 CFR 900.2(aa) and 900.12(c)). A diagnostic unilateral mammogram after a call-back still gets a density assessment and a lay summary with the FDA statement. A male patient, a transgender patient, or a post-mastectomy patient who has a mammogram under the certificate is not a loophole FDA published; the facility follows 900.12(c) for each mammographic examination it performs.

Result-communication clocks from Section 7.1 still apply. Density does not create a new deadline. Suspicious or Highly Suggestive of Malignancy still moves the provider report and the lay summary to 7 calendar days from final interpretation. Other assessments remain on the 30-calendar-day lay-summary clock. Density is an additional required content element inside those same letters and reports.

Alternative Standard #26 (July 2025)

FDA approved MQSA Alternative Standard #26 on July 11, 2025, effective immediately, with no time limit, and available to all facilities subject to MQSA. The original regulation uses plural breasts ("The breasts are almost entirely fatty"). That wording is awkward on a unilateral exam. Alternative Standard #26 lets the interpreting physician use singular phrasing or phrasing that is neither singular nor plural:

• "The breast is almost entirely fatty." / "The breast is heterogeneously dense, which may obscure small masses." / "The breast is extremely dense, which lowers the sensitivity of mammography."
• "Breast Density: Almost entirely fatty" / "Breast Density: Scattered areas of fibroglandular density" / "Breast Density: Heterogeneously dense, which may obscure small masses" / "Breast Density: Extremely dense, which lowers the sensitivity of mammography."

The lay-summary statements themselves stay the same FDA paragraphs quoted above. Singular or "Breast Density:" labels on the report still map to the same not-dense versus dense letters. Mention Alternative Standard #26 on the exam as the FDA-approved way to word a unilateral density assessment, not as permission to skip density on diagnostic or one-breast studies.

Mammographer workflow that survives an inspection

1. Perform the mammogram. Label images under 21 CFR 900.12(c)(5). Do not put a density category on the image as if it were a view code.
2. If the patient asks, explain that the interpreting physician will assign density and that the lay letter includes federal language about dense versus not dense tissue.
3. After interpretation, confirm the facility's report template offers the four FDA assessments (or Alternative Standard #26 equivalents) and that the lay-summary engine pulls the matching FDA paragraph — not a State-only leftover sentence and not a marketing rewrite.
4. Know which letter went out. If a patient calls and says "my letter does not mention density," that is a results-communication problem and can become a serious complaint if reports or lay summaries are not sent as required.

Density reporting is not a technologist diagnosis. It is an MQSA content rule that makes the IP's assessment visible to the provider and the patient in words FDA wrote. The mammographer's job is to produce interpretable images, to refuse to freelance a density category, and to make sure the facility's letters still say what FDA requires.